Literature DB >> 35136814

Black fungus: Possible causes of surge in cases in the second pandemic in India.

Shyam Kishor Kumar1, Suprabha Chandran2, Aroop Mohanty3, Mithilesh Kumar Jha4.   

Abstract

Entities:  

Year:  2021        PMID: 35136814      PMCID: PMC8797135          DOI: 10.4103/jfmpc.jfmpc_1183_21

Source DB:  PubMed          Journal:  J Family Med Prim Care        ISSN: 2249-4863


× No keyword cloud information.
Dear Editor, In India, as the second wave of COVID-19 engulfed the entire nation, another threat colloquially known as “Black Fungus” imposed a new challenge to the medical world. In real sense, black fungus is nothing, but an infection of mucormycetes known as mucormycosis. This is the third most common cause of invasive fungal infection next to Aspergillus and Candida spp.[1] Rhizopus oryzae is the most common fungus, which is responsible for approximately 60% of cases of mucormycosis.[2] This is an opportunistic pathogen that is angioinvasive in nature. Lesions appear as black spots in the nasal cavity, mouth and throat and so named as “black fungus”. In early May of 2021, a sudden increase in cases of mucormycosis was noted. Due to the continuous rising of cases, the Union Health Ministry on Thursday, 20 May 2021 urged the states to make mucormycosis, a notifiable disease under the Epidemic Diseases Act 1897. There were about 12,000 cases of mucormycosis up to 6 June 2021.[3] Government of India stated on 8 June 2021 that the total cases of mucormycosis were 28,252, of which 86% cases had a history of COVID-19 and 62.3% with a history of diabetes. Maharashtra reported the maximum number of mucormycosis cases (6339) followed by Gujarat (5486).[4] Mortality rate is 40%–80% but it may vary upon different underlying conditions.[5] There are several risk factors of mucormycosis such as diabetes mellitus, haematological malignancy, organ transplant or stem cell transplant patients, neutropenia, increased iron level, deferoxamine.[6] In the current scenario of COVID-19 pandemic, diabetes is still the main predisposing factor of mucormycosis as suggested by several studies as well.[257] Mucor utilises glucose and so grows fast in excess blood glucose level.[8] Diabetes fulfils this criterion. Another factor is that diabetes causes persistent hyperglycaemia that is responsible for impaired chemotaxis and phagocytosis of neutrophils. In addition to this, diabetic ketoacidosis impairs the binding of iron to transferrin leading to increase in free iron level which promotes fungal growth.[5] Irrational use of corticosteroids is also a predisposing factor for mucormycosis. Although the Ministry of Health and Family Welfare (MoHFW) recommends intravenous methylprednisolone/dexamethasone for moderate or severe cases,[9] indiscriminate use or longer use may pose a problem due to immunosuppression and by causing hyperglycaemia both in diabetic or non-diabetic patient.[2510] Furthermore, steroid takes 4 weeks to wear off its effect, so patients treated with steroids should protect themselves during this period and they should avoid to visit damp and dusty area. If it is unavoidable, they should wear three-ply mask, gloves and fully cover legs and arms. Furthermore, oxygen mask and canula should be sterile and water used for oxygenation should be regularly checked for patient on oxygen. COVID-19 causes sustained lymphopenia being reported in 85% of cases.[11] So, there is decrease in number of T cells, CD4 cells and CD8 cells. This decreased count of T cells makes a person prone to fungal co-infections. COVID-19 also cause excessive lung damage and alveolo-interstitial pathology. It makes a favourable chance of fungal infection.[1213] Kochi chapter of Indian Medical Association, experts suggested that excessive steam inhalation may lead to mucomycosis. Data in India reveal that 10%–20% of patients have mucormycosis due to steam inhalation.[14] Nasal mucosa is very delicate structure that may get damaged due to high temperature. Breached mucosa affects protective escalatory function leading to invasive fungal infection. Some experts plead that use of industrial oxygen over medical oxygen may be the culprit of fungal infection. Due to the sudden rise of cases and decrease supply of medical oxygen, hospitals were diverted to use of industrial oxygen. Medical oxygen is highly purified. Before being used, it undergoes different processes such as compression, filtration and purification.[15] Its cylinders are cleaned and disinfected also. But these criteria are not fulfilled by industrial oxygen. So, use of uncleaned industrial oxygen may be a probable cause of the black fungus surge. Mucormycosis should always be taken into consideration when a patient at risk presents with unilateral facial swelling, proptosis, facial pain or swelling. Diagnosis is based on combination of clinical symptoms, radiological findings, histopathological examinations and microbiological culture. Radiology is helpful for determination of extent of disease. A combined approach is followed for treatment. Patients with mucormycosis are undergone with exenteration of affected part and administration of intravenous liposomal amphotericin B (5-10 mg/kg/day) along with blood sugar control. It is utmost important to initiate treatment as the earliest because a delay of 6 days may lead to doubling of mortality.[5]

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  10 in total

1.  Rhinocerebral mucormycosis in COVID-19 patient with diabetes a deadly trio: Case series from the north-western part of India.

Authors:  Hardeva Ram Nehara; Inder Puri; Vipin Singhal; Sunil Ih; Bhagirath Ram Bishnoi; Pramendra Sirohi
Journal:  Indian J Med Microbiol       Date:  2021-05-26       Impact factor: 0.985

Review 2.  High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections.

Authors:  Kinal Bhatt; Arjola Agolli; Mehrie H Patel; Radhika Garimella; Madhuri Devi; Efrain Garcia; Harshad Amin; Carlos Domingue; Roberto Guerra Del Castillo; Marcos Sanchez-Gonzalez
Journal:  Discoveries (Craiova)       Date:  2021-03-31

3.  Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case Report and Systematic Review of Literature.

Authors:  Deepak Garg; Valliappan Muthu; Inderpaul Singh Sehgal; Raja Ramachandran; Harsimran Kaur; Ashish Bhalla; Goverdhan D Puri; Arunaloke Chakrabarti; Ritesh Agarwal
Journal:  Mycopathologia       Date:  2021-02-05       Impact factor: 2.574

4.  COVID-19 and orbital mucormycosis.

Authors:  Sandip Sarkar; Tanmay Gokhale; Sushmita Sana Choudhury; Amit Kumar Deb
Journal:  Indian J Ophthalmol       Date:  2021-04       Impact factor: 1.848

Review 5.  COVID-19 and Eye: A Review of Ophthalmic Manifestations of COVID-19.

Authors:  Mrittika Sen; Santosh G Honavar; Namrata Sharma; Mahipal S Sachdev
Journal:  Indian J Ophthalmol       Date:  2021-03       Impact factor: 1.848

6.  A Case of Fatal Rhino-Orbital Mucormycosis Associated With New Onset Diabetic Ketoacidosis and COVID-19.

Authors:  Salomon Waizel-Haiat; Jose Alberto Guerrero-Paz; Luis Sanchez-Hurtado; Salvador Calleja-Alarcon; Laura Romero-Gutierrez
Journal:  Cureus       Date:  2021-02-05

7.  Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India.

Authors:  Awadhesh Kumar Singh; Ritu Singh; Shashank R Joshi; Anoop Misra
Journal:  Diabetes Metab Syndr       Date:  2021-05-21

8.  Rise of the phoenix: Mucormycosis in COVID-19 times.

Authors:  Swati A Ravani; Garima A Agrawal; Parth A Leuva; Palak H Modi; Krisha D Amin
Journal:  Indian J Ophthalmol       Date:  2021-06       Impact factor: 1.848

9.  Opportunistic Fungal Infections in the Epidemic Area of COVID-19: A Clinical and Diagnostic Perspective from Iran.

Authors:  Mohammadreza Salehi; Kazem Ahmadikia; Hamid Badali; Sadegh Khodavaisy
Journal:  Mycopathologia       Date:  2020-07-31       Impact factor: 2.574

  10 in total
  2 in total

1.  Histomorphological features of mucormycosis with rise and fall of COVID-19 pandemic.

Authors:  Nidhya Ganesan; Shanthakumari Sivanandam
Journal:  Pathol Res Pract       Date:  2022-06-17       Impact factor: 3.309

Review 2.  Mucormycosis in the COVID-19 Environment: A Multifaceted Complication.

Authors:  Rohit Sharma; Praveen Kumar; Abdur Rauf; Ashun Chaudhary; Pradeep Kumar Prajapati; Talha Bin Emran; Clara Mariana Gonçalves Lima; Carlos Adam Conte-Junior
Journal:  Front Cell Infect Microbiol       Date:  2022-07-18       Impact factor: 6.073

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.